NCT02538627View on ClinicalTrials.gov

Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib

PHASE1TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

October 5, 2016

Study Completion Date

October 5, 2016

Conditions
Colorectal CancerNon-small Cell Lung CancerSquamous Cell Carcinoma of the Head and Neck
Interventions
DRUG

MM-151

MM-151

DRUG

MM-121

MM-121

DRUG

MM-141

MM-141

DRUG

trametinib

trametininb

Trial Locations (5)

30342

Northside Hospital, Sandy Springs

37235

Vanderbilt, Nashville

60611

Northwestern, Chicago

63110

Washington University, St Louis

80045

University of Colorado, Aurora

Sponsors
All Listed Sponsors
lead

Merrimack Pharmaceuticals

INDUSTRY

NCT02538627 - Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib | Biotech Hunter | Biotech Hunter